(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) today will present updated interim results from its ongoing Phase 1/2 study of MRT-2359 in patients with metastatic castration-resistant prostate ...
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily ...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, ...
Shares of Monte Rosa TherapeuticsGLUE surged to a nearly four-year high Tuesday after the biotech company said all four patients in a prostate cancer study responded to its experimental treatment.
Add Yahoo as a preferred source to see more of our stories on Google. WASHINGTON (DC News Now) — September is Prostate Cancer Awareness Month, and according to the National Cancer Institute (NCI), ...
An MRI before treatment in men undergoing radical prostatectomy can provide independent prognostic value for oncologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results